La tunisie Medicale - 2021 ; Vol 99 ( n°05 ) : 560-568
[ Vu 1120 fois ]
Résumé

Abstract
Background: Lung cancer is the leading cause of cancer mortality worldwide. Even after radical resection, the rate of recurrence of non-small cell lung cancer remains high.
Aim: To identify the profile of patients operated for lung cancer and to study the prognostic factors of tumor recurrence.
Methods: We performed a retrospective study including 67 cases of lung cancer with curative surgery, hospitalized between 2010 and 2016.
Results: The mean age was 61 years. The sex ratio was 21. The average time to diagnosis was 22 days. The average time to start treatment was 10 days. The most common histological type was adenocarcinoma (63%). Lobectomy was performed in 63% of the patients.
Tumor recurrence was noted in 40% of the patients. The average time between recurrence and the surgical treatment was 12 months. The most common location of recurrence was the lung (70%). Recurrence was more common among adenocarcinoma and smokers older than 60 years. The majority of locally advanced and metastatic cancers have recurred.
The average survival was 56 ± 4months. Better survival rates were observed in young patients, with less than 25 pack-years of early-stage, no lymph node involvement, and patients who received adjuvant chemotherapy. The probability of survival was 5 years for all tumor stages.
Conclusion: The prognostic factors for recurrence after radical resection for lung cancer were: the age of patients, smoking history, histological type, tumor stage, and surgical procedure.

Mots Clés
Article
Références
  1. 1. Locatelli-Sanchez M, Couraud S, Souquet J. Épidémiologie du cancer bronchique : données actuelles. Rev Mal Respir Actual. 2015;7(4):285 7. 2. Ben Abdallah M, Zehani S, Hizem Ben Ayoub W. Registre des Cancers Nord-Tunisie (Données 2007-2009). Ministère de la Santé Publique. Institut Salah Azaiez, Tunis, 2015. 3. Dela Cruz CS, Tanoue LT, Matthay RA. Lung Cancer: Epidemiology, Etiology, and Prevention. Clin Chest Med. 2011;32(4):605 44. 4. Rami-Porta R, Crowley JJ, Goldstraw P. The Revised TNM Staging System for Lung Cancer. 2009;15(1):7. 5. World Medical Association. (‎2001)‎. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects.. Bulletin of the World Health Organization, 79 (‎4)‎, 373 - 374. World Health Organization. 6. Schreibert G, McCory DC. Performance Characteristics of different Modalities for Diagnosis of Suspected Lung Cancer: Summary of Published Evidence. Chest. 2003;123 Suppl 1:S115 28. 7. Riquet M, Berna P. CBNPC de stades précoces (I. II. IIIA) Quelle est la meilleure stratégie thérapeutique ? Rev Mal Respir. 2006;23(5):36 42. 8. Institut national du cancer. Cancer du poumon, Bilan initial, Collection Recommandations et référentiels. Boulogne-Billancourt: INCa; 2011. 9. Cadelis G. Epidimiologie et incidence du cancer bronchique primitif dans une region à faible consommation tabagique: la Guadeloupe. Données 2008-2009 du registre des cancers. Rev Mal Respir. 2013;30(7):537 48. 10. Yilmaz A, Damadoglu E, Salturk C, Okur E, Tuncer LY, Halezeroglu S. Delays in the diagnosis and treatment of primary lung cancer: are longer delays associated with advanced pathological stage? Ups J Med Sci. 2008;113:287 96. 11. British thoracic society. BTS recommendations to respiratory physicians for organising the care of patients with lung cancer. The lung cancer working party of the BTS standards of care committee. Thorax. 1998;53 Supp 1:S1 8. 12. Ben Saad S, Chaouch N, Racil H, Rekhis O, Greb D, Bousnina S, et al. Pronostic et suivi du cancer broncho-pulmonaire opéré. Rev Mal Respir. 2007;24(HS1):89. 13. Grivaux MG, Locher CL, Goupil FG, Asselain BA, Coëtmeur DC, Collon TC, et al. Cancer bronchique opéré : étude ESCAP-2011-CPHG-. Rev Mal Respir. 2015;32(2):A45. 14. Pinquié F, Goupil F, Oster JP, Dixmier A, Renault PA, Lévy A, et al. Stratégies thérapeutiques chez les patients opérés pour un carcinome bronchique non à petites cellules. Résultats de l’étude ESCAP-2011-CPHG réalisée par le Collège des pneumologues des hôpitaux généraux (CPHG). Rev Mal Respir. 34(9):976 90. 15. Mouroux J, Venissac N, Pop D, Nadeemy S. La chirurgie du cancer bronchopulmonaire. J Radiol. 2009;90(7):980 90. 16. Kent M, Landreneau R, Mandrekar S, Hillman S, Nichols F, Jones D, et al. Segmentectomy versus wedge resection for non-small cell lung cancer in high-risk operable patients. Ann Thorac Surg. 2013;96:1747 55. 17. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718 23. 18. Song WA, Zhou NK, Wang W, Chu WY, Liang CY, Tian XD, et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer. An updated metaanalysis of 13 randomized controlled trials. J Thorac Oncol. 2010;5(4):510 6. 19. Brosseau S. Traitements péri-opératoires des carcinomes bronchiques non à petites cellules. Rev Mal Respir. 2017;34(6):618 34. 20. Hellman S, Weicheselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8 10. 21. Younes RN, Gross JL, Deheinzelin D. Follow-up in lung cancer: how often and for what purpose? Chest. 1999;115:1494 9. 22. Gauger J, Patz EF, Coleman RE, Herndon JE. Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence. J Thorac Oncol. 2007;2:499‑505. 23. Peters S, Weder W, Dafni U. Lungscape: résection du cancer du poumon non à petites cellules réséqué par des paramètres cliniques et pathologiques. J Thorac Oncol. 2014;9:1675 84. 24. Westeel V, Choma D, Clement F, Woronoff-Lemsi MC, Pugin JF, Dubiez A. Relevance of an intensive postoperative follow up, after surgery for non-small cell lung cancer. Ann Thorac Surg. 2000;(70):1185 90. 25. Lou F, Huang J, Sima CS, Dycoco J, Rusch V, Bach PB. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg. 2013;145(1):75 81. 26. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60(3):615 22. 27. Ching-Feng Wu, Jui-Ying Fu, Chi-Ju Yeh, Yun-Hen Liu, Ming-Ju Hsieh, Yi-Cheng Wu. Recurrence Risk Factors Analysis for Stage I Non-small Cell Lung Cancer. Médecine. 2015;94(32):e1337. 28. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561 71. 29. Saynak M, Veeramachaneni NK, Hubbs JL, Nam J, Qaqish BF, Bailey JE, et al. Local failure after complete resection of N0–1 non-small cell lung cancer. Lung Cancer. 2011;71(2):156 65. 30. Siegel R, Naishadham D, Jemal A. A Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11 30. 31. Bréchot JM. Facteurs pronostiques et prédictifs dans le cancer bronchique non à petites cellules : données actuelles. Oncologie. 2005;7:443 6. 32. Toumi Daghrour I. Facteurs pronostiques du cancer broncho-pulmonaire opéré. A propos de 1405 cas [Thèse]. Médecine: Tunis; 2013. 73p. 33. Braham W, Debboussi S, Darouaz S, Boudawara N, Regaieg H, Boussoffara L, et al. Facteurs pronostiques des cancers bronchiques non à petites cellules (CBNPC) opérés : à propos de 91 cas. Rev Mal Respir. 2009;26(HS1):54.
Espace membre
E-mail :
Mot passe :
Mémoriser Mot de passe oublié S'inscrire
Archives
2021
Janvier
Février
Mars
Avril
Mai
Juin
Juillet
Août
Septembre
Octobre
Novembre
Décembre
Mots-clés
Enfant traitement pronostic Chirurgie diagnostic Tunisie Maladie de crohn Cancer dépistage Cancer du sein Coelioscopie Immunohistochimie mammographie Ostéoporose échographie
Newsletter
S'inscrire pour recevoir les newsletters
E-mail :
Partagez
Rejoignez-nous !